Related Experiment Video
Updated: May 27, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
[Determining cardiovascular risk in patients with rheumatoid arthritis: waiting for trial outcomes is not
1VU medisch centrum, afd. Interne Geneeskunde, Amsterdam, the Netherlands. mt.nurmohamed@planet.nl
Insights
Patients with rheumatoid arthritis (RA) face cardiovascular risks comparable to those with diabetes. Early cardiovascular risk management, including anti-inflammatory therapy and medications like statins, is crucial for RA patients.
Area of Science:
- Rheumatology
- Cardiology
- Pharmacology
Context:
- Patients with rheumatoid arthritis (RA) exhibit cardiovascular disease (CVD) risk comparable to individuals with diabetes.
- The chronic inflammatory nature of RA significantly contributes to elevated CVD risk.
- Current guidelines recommend aggressive cardiovascular risk management for RA patients.
Purpose:
- To emphasize the critical need for cardiovascular risk management in rheumatoid arthritis (RA) patients.
- To highlight the comparable CVD risk between RA patients and diabetic patients.
- To advocate for the use of anti-inflammatory therapies, statins, and antihypertensives in RA management.
Summary:
- Cardiovascular risk management is essential for rheumatoid arthritis (RA) patients due to their high risk, similar to diabetes patients.
- While specific cardiovascular endpoint trials in RA are limited, existing evidence suggests statins and antihypertensives are effective.
- Therapy should focus on suppressing chronic inflammation and utilizing indicated statins and/or antihypertensives.
Impact:
- Implementing comprehensive cardiovascular risk management strategies can potentially reduce CVD incidence in RA.
- This approach underscores the importance of a multidisciplinary approach involving rheumatologists and cardiologists.
- Further clinical monitoring is necessary to confirm the long-term benefits of these interventions on cardiovascular outcomes in RA.
Abstract:
Cardiovascular risk management is clearly indicated in patients with rheumatoid arthritis (RA) today because this risk is comparable to patients with diabetes. Although formal evidence of cardiovascular endpoint trials with statins and/or antihypertensives is lacking in patients with RA, there are no indications that these drugs will have limited effect. In contrast, there is accumulating evidence as to the efficacy of the use of these drugs in RA that is at least comparable to their effects in the general population. All patients with RA should therefore receive cardiovascular risk-management therapy aimed at powerful suppression of the chronic inflammatory process as well as treatment with statins and/or antihypertensives, if indicated. Obviously, monitoring in the clinical setting is necessary to document if such therapy does indeed reduce cardiovascular disease in patients with RA.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease IV: Nursing Management
Atherosclerosis III: Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
